Similar associations between the proportion of KRAS mutations in patients with mutant PIK3CA and wtPIK3CA, although not always statistically significant perhaps because of smaller numbers of patients, were found in disease-specific subanalysis in colorectal cancer (13/18 [72%] vs. 36/79 [46%]; p = 0.07), ovarian cancer (4/7 [57%] vs. 1/39 [3%]; p = 0.001), and all tested cancers excluding colorectal (6/32 [19%] vs. 14/238 [6%]; p = 0.02) (Figure 4B–D). This evidence concerns the gene PIK3CA and colorectal cancer.